Royalty Pharma announced Thursday morning that it has acquired an interest in PureTech Health’s royalty in Karuna Therapeutics’ schizophrenia treatment KarXT for up to $500 million. As per the terms ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results